MUC16 and cancer: Regarding MUC16-derived HLA class I peptides, we found that cancers of nodal-positive patients presented more MUC16-derived peptides than those of patients without lymph node metastases (p-value 0.04, Figure 1B), whereas no differences were found for the other parameters (Figure 1B and Figure S2B).